Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  4.00 1.17% 347.00 170,646 16:29:53
Bid Price Offer Price High Price Low Price Open Price
347.00 348.00 353.00 335.50 336.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.61 13.87 1.46 241.6 992
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:15 O 71 347.017 GBX

Puretech Health (PRTC) Latest News

More Puretech Health News
Puretech Health Investors    Puretech Health Takeover Rumours

Puretech Health (PRTC) Discussions and Chat

Puretech Health Forums and Chat

Date Time Title Posts
17/6/202115:52PureTech Health - innovative healthcare1,211
22/7/201821:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech Health (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Puretech Health trades in real-time

Puretech Health (PRTC) Top Chat Posts

Puretech Health Daily Update: Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 343p.
Puretech Health Plc has a 4 week average price of 335.50p and a 12 week average price of 335.50p.
The 1 year high share price is 446p while the 1 year low share price is currently 232.50p.
There are currently 285,898,746 shares in issue and the average daily traded volume is 271,077 shares. The market capitalisation of Puretech Health Plc is £992,068,648.62.
mighunter: Liberum mark Puretech as joint top pick in medical sector this morning (other is Medica MGP), reiterating PRTC buy with PT of 540p.
rambutan2: I assume reason for today's rise: BOSTON, Mass. – May 26, 2021 – Akili Interactive (“Akili” or “Company”), maker of EndeavorRx™, the first and only prescription video game treatment, today announced $160M in combined equity and debt financing. Akili is a pioneer of a new class of medicine and treatments that are not only effective and clinically-validated but that deliver amazing experiences to patients. The Company’s flagship product made history in June 2020 when it received U.S. Food and Drug Administration (FDA) clearance. With the completion of the oversubscribed Series D financing, Akili will continue to push the boundaries of traditional medicine to deliver on the promise of digital therapeutics for patients. The $110M Series D equity financing was led by Neuberger Berman Funds and joined by new investors Polaris Partners; Mirae Assets; Shionogi & Co., Ltd., New Leaf Venture Partners; Dave Baszucki, Founder and CEO of Roblox Corporation; QUAD Investment Management, and Ladera Venture Partners. Existing Akili investors Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, and M Ventures (the corporate VC fund of Merck KGaA, Darmstadt, Germany) all participated in the financing round.
rambutan2: Interesting to see where the two US analysts currently covering PRTC stand: 15/01/21: SVB Leerink analyst Thomas J. Smith initiated coverage of PureTech Health with an Outperform rating and $70 price target. Smith says LYT-100, a deuterated form of Pirfenidone, has demonstrated potentially improved PK and safety/tolerability relative to the parent molecule, and is currently being evaluated in Phase 2 trials to treat breast cancer-related lymphedema and post-acute COVID-19 respiratory complications, while the company is also planning to advance LYT-100 in progressive-fibrotic interstitial lung diseases including idiopathic pulmonary fibrosis, where the analyst believes LYT-100 could differentiate on better safety/tolerability, potentially enhanced efficacy, and less frequent dosing that could displace Pirfenidone as backbone standard of care. 10/02/21: Piper Sandler analyst Edward Tenthoff raised the firm's price target on PureTech Health (PRTC) to $76 from $66 and reiterates an Overweight rating on the shares. Puretech sold 1M Karuna Therapeutics (KRTX) shares for $118M and still holds 2.4M shares or about 9% of Karuna, Tenthoff tells investors in a research note. Separately, Vor Biopharma (VOR) completed a successful initial public offering and PureTech retains 3.2M Vor shares, the analyst adds. These two deals account for the target raise.
lendmeafiver: You are absolutely right, zero value attributed to it in the share price at the moment, I believe Peel Hunts recent uplifted target price was partly to reflect the value of the internal pipeline.
volvo: The the doubling action on VOR and the Karuna topping $120 added quite literally added over $100m to Puretech as additional assets....UK market gives it $ VOR plus Karuna $520m, thats insane Vedanta IPO is already eagerly awaiting, more than VOR is/was. Vedanta could see $1 billion added to Puretech's coffers at launch.....or £730m nearly 3/4 the share price, because anyone can see nothing is in the share price yet
volvo: Daphne spells it out at 5 minutes into her Credit Suisse presention last Thursday..... abridged version.... The board of directors can see a clear share price disconnect between our achievements to date and our share price, blames directly the London listing for the SIGNIFICANT discount, then compares the cash of $387m and the 12 pc stake in Karuna $350 as virtually equating to the current share price so everything else for free, 8 founded entities, and the associated royalties and all of the wholly owned pipeline, THEN she says that is why they are listed on the NASDAQ to achieve proper market value Listen to it and sit back and imagine how high the shares will go in the USA. Daphne is beating the drum and rightly so.
deadly nightshade: excellent thanks volvo roll on monday i can't wait, be good if we can see the back of these ii's then hopefully after the share price will find its true level rather then constant selling by them into any rise that way hindering the share price
lendmeafiver: what the PRTC Share Price?
lendmeafiver: Further good news flow here today and KRTX looking solid, whilst the PRTC share price seems to be all over the place on minimal volume.
lendmeafiver: Agree. Surely given recent progress an ipo or other transaction at Gelesis has to be on the cards, will have a huge impact on the Prtc share price I expect.
Puretech Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Puretech H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 21:17:07